Dohi K, Fujioka M, Nakamoto Y
Acta Pathol Jpn. 1982 Nov;32(6):1047-52. doi: 10.1111/j.1440-1827.1982.tb02084.x.
Effects of heparin, urokinase, and ancrod were concurrently compared on intraglomerular coagulation using a model of progressive Masugi nephritis. Evaluations were performed with light and immunofluorescent microscopy. Treatment significantly reduced crescent formation, more markedly with ancrod. In contrast, endocapillary proliferation was enhanced in the groups treated with urokinase and, especially, ancrod. Ancrod appeared to be most effective in decreasing the glomerular deposition of fibrinogen-related materials as judged from the immunofluorescence, and a relatively high dose was required for urokinase to be comparable with ancrod. However, in some glomeruli from two of 13 animals given ancrod, mesangiolytic lesion developed. Thus, although promising, ancrod has many problems to be solved before using it to control endocapillary proliferation and mesangiolysis.
使用进行性马杉肾炎模型，同时比较了肝素、尿激酶和安克洛酶对肾小球内凝血的影响。通过光学显微镜和免疫荧光显微镜进行评估。治疗显著减少了新月体形成，安克洛酶的效果更显著。相比之下，尿激酶治疗组尤其是安克洛酶治疗组的毛细血管内增生增强。从免疫荧光判断，安克洛酶在减少纤维蛋白原相关物质的肾小球沉积方面似乎最有效，尿激酶需要相对高的剂量才能与安克洛酶相当。然而，在接受安克洛酶治疗的13只动物中的2只的一些肾小球中，出现了系膜溶解病变。因此，尽管前景广阔，但在将安克洛酶用于控制毛细血管内增生和系膜溶解之前，还有许多问题需要解决。
